Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-17T10:26:03.105Z Has data issue: false hasContentIssue false
  • English
  • Français

Statins May Act Through Increasing Tissue Plasminogen Activator/Plasmin Activity to Lower Risk of Alzheimer's Disease

Published online by Cambridge University Press:  07 November 2014

Shih-Jen Tsai
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Communique
Information
CNS Spectrums , Volume 14 , Issue 5 , May 2009 , pp. 234 - 235
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Rockwood, K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:71–77.Google Scholar
2.Crisby, M, Carlson, LA, Winblad, B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:131–136.Google Scholar
3.Sparks, DL, Sabbagh, M, Connor, D, et al.Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:78–86.Google Scholar
4.Ledesma, MD, Dotti, CG. The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp. 2005;72:129–38.Google Scholar
5.Friedhoff, LT, Cullen, El, Geoghagen, NS, Buxbaum, JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol. 2001;4:127–130.Google Scholar
6.Melchor, JP, Strickland, S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005;93:655–660.Google Scholar
7.Essig, M, Vrtovsnik, F, Nguyen, G, Sraer, JD, Friedlander, G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol. 1998;9:1377–1388.Google Scholar
8.Lopez, S, Peiretti, F, Bonardo, B, Juhan-Vague, I, Nalbone, G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152:359–366.Google Scholar
9.Mussoni, L, Banfi, C, Sironi, L, Arpaia, M, Tremoli, E. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost. 2000;84:59–64.Google Scholar
10.Ledesma, MD, Da Silva, JS, Crassaerts, K, Delacourte, A, De Strooper, B, Dotti, CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 2000;1:530–535.Google Scholar
11.Ledesma, MD, Abad-Rodriguez, J, Galvan, C, et al.Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep. 2003;4:1190–1196.Google Scholar
12.Murer, MG, Yan, Q, Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001;63:71–124.Google Scholar
13.Nagahara, AH, Merrill, DA, Coppola, G, et al.Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. In press.Google Scholar
14.Pang, PT, Teng, HK, Zaitsev, E, et al.Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487–491.Google Scholar
15.Barnes, P, Thomas, KL. Proteolysis of proBDNF is a key regulator in the formation of memory. PLoS ONE. 2008;3:e3248.Google Scholar
16.Lu, B, Pang, PT, Woo, NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603–614.Google Scholar
17.Corder, EH, Saunders, AM, Strittmatter, WJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923.Google Scholar